Home Department: Bioengineering
Mentor: Tanya Stoyanova (Radiology)

“Combination with Notch1 Antibody Enhances Second-generation Anti-androgen Treatments in Aggressive Prostate Cancers”

Prostate cancer is the most common cancer and the second leading cause of cancer death in men. While prostate cancers initially respond to first-line, anti-hormonal therapies, aggressive subtypes can emerge and become resistant to anti-androgen treatments. Thus, re-sensitizing these resistant cancers can improve patient prognosis and survival. Notch1 signaling pathway has been identified as a critical factor in prostate cancer proliferation and invasion. Both Notch1 inhibition and deletion were synergistic with anti-androgen therapies. Thus, the goal of Michelle's project is to test the therapeutic efficacy of combination therapy between the Notch1-inhibiting antibody, Brontictuzumab, and anti-androgen treatments in aggressive prostate cancers.